CLEVELAND, Ohio (WOIO) – A spokesperson for the Cleveland Clinic has confirmed that the hospital system will not administer a controversial Alzheimer’s drug recently approved by the Food and Drug Administration.
Aducanumab, marketed as Aduhelm, is the first new drug for Alzheimer’s disease in almost 20 years, according to an Associated Press report. But many independent experts say the drug “has not been shown to help slow destructive brain disease,” reports the AP.
“A multidisciplinary panel of experts from the Cleveland Clinic reviewed all of the scientific evidence available on this drug. Based on current data regarding its safety and efficacy, we have decided not to offer aducanumab at this time, ”the clinic said in a statement.
The spokesperson said the clinic will reconsider its decision as more research is completed.
One study showed aducanumab did not reverse mental decline but slowed its progression, according to the AP. The FDA is asking Biogen, the drug’s developer, to conduct a follow-up study. The FDA may withdraw the drug if a second study shows it doesn’t benefit patients with Alzheimer’s disease, the AP reports.
Copyright 2021 WOIO. All rights reserved.